XNCR: Xencor, Inc. Stock

by  •  • Comments Off on XNCR: Xencor, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 746.90
Enterprise Value ($M) 866.04
Book Value ($M) 674.03
Book Value / Share 9.57
Price / Book 1.11
NCAV ($M) 299.68
NCAV / Share 4.25
Price / NCAV 2.49

Profitability (mra)
Return on Invested Capital (ROIC) -0.26
Return on Assets (ROA) -0.26
Return on Equity (ROE) -0.38

Liquidity (mrq)
Quick Ratio 6.61
Current Ratio 6.61

Balance Sheet (mrq) ($M)
Current Assets 577.60
Assets 951.95
Liabilities 277.92
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 110.49
Operating Income -176.08
Net Income -232.62
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -202.19
Cash from Investing -7.87
Cash from Financing 197.15

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
1 day ago 13G/A BlackRock, Inc. 15.80 -8.78
11-14 13G/A EcoR1 Capital, LLC 9.40 27.20
11-14 13G/A Price T Rowe Associates Inc /md/ 5.60 12.58
11-12 13G/A Primecap Management Co/ca/ 13.08 2.65
10-18 13G/A State Street Corp 4.50 -6.24

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 o TRANSITION REPORT PURSUANT
2025-02-24 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1)
2025-02-24 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1)
2025-02-24 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1)
2025-02-24 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 o TRANSI
2024-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-08-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-29 91,113 437,985 20.80
2025-04-28 77,668 270,969 28.66
2025-04-25 94,960 376,998 25.19
2025-04-24 129,310 510,537 25.33

(click for more detail)

Similar Companies
VRCA – Verrica Pharmaceuticals Inc. WVE – Wave Life Sciences Ltd.
XENE – Xenon Pharmaceuticals Inc. XOMA – XOMA Royalty Corporation


Financial data and stock pages provided by
Fintel.io